CD47 and cancer: These findings led to novel therapeutic approaches targeting CD47 or SIRP1α (i.e., anti-CD47 antibodies such as Hu5F9-G4 or CC90002 and competitive recombinant SIRP1αFC such as TTI-621 and ALX148) as a way to reeducate TAMs for eliminating cancer cells in humans (Figure 3) [124,125].